title: Electrophysiologic correlations with clinical outcomes in CIDP.
abstract: Data are lacking on correlations between changes in nerve conduction (NC) studies and treatment response in chronic inflammatory demyelinating polyneuropathy (CIDP). This report examined data from a randomized, double-blind trial of immune globulin intravenous, 10% caprylate/chromatography purified (IGIV-C [Gamunex]; n = 59) versus placebo (n = 58) every 3 weeks for up to 24 weeks in CIDP. Motor NC results and clinical measures were assessed at baseline and endpoint/week 24. Improvement from baseline in adjusted inflammatory neuropathy cause and treatment score correlated with improvement in proximally evoked compound muscle action potential (CMAP) amplitudes (r = -0.53; P < 0.001) of all nerves tested and with improvement in CMAP amplitude of the most severely affected motor nerve (r = -0.36; P < 0.001). Correlations were observed between improvement in averaged CMAP amplitudes and dominant-hand grip strength (r = 0.44; P < 0.001) and Medical Research Council sum score (r = 0.38; P < 0.001). Overall, the change in electrophysiologic measures of NC in CIDP correlated with clinical response to treatment.
authors.affiliation: Division of Neurology, University Health Network, 5EC-309, Toronto General Hospital, 200 Elizabeth Street, Toronto, ON, M5G 2C4 Canada. vera.bril@utoronto.ca
authors.forename: Vera
authors.initials: V
authors.lastname: Bril
authors.forename: Marta
authors.initials: M
authors.lastname: Banach
authors.forename: Marinos C
authors.initials: MC
authors.lastname: Dalakas
authors.forename: Chunqin
authors.initials: C
authors.lastname: Deng
authors.forename: Peter
authors.initials: P
authors.lastname: Donofrio
authors.forename: Kim
authors.initials: K
authors.lastname: Hanna
authors.forename: Hans-Peter
authors.initials: HP
authors.lastname: Hartung
authors.forename: Richard A C
authors.initials: RA
authors.lastname: Hughes
authors.forename: Hans
authors.initials: H
authors.lastname: Katzberg
authors.forename: Norman
authors.initials: N
authors.lastname: Latov
authors.forename: Ingemar S J
authors.initials: IS
authors.lastname: Merkies
authors.forename: Pieter A
authors.initials: PA
authors.lastname: Van Doorn
mesh_terms: D000200:Action Potentials; D000328:Adult; D000368:Aged; D002210:Caprylates / Q000008:administration & dosage*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D055724:Electrophysiological Phenomena; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D008875:Middle Aged; D009046:Motor Neurons; D009431:Neural Conduction; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000188:drug therapy* / Q000503:physiopathology*; D016896:Treatment Outcome
chemical_list: D002210:Caprylates; D016756:Immunoglobulins, Intravenous